NI-57
NI-57 性质
| 沸点 | 580.1±60.0 °C(Predicted) |
|---|---|
| 密度 | 1.43±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO 中≤25mg/ml；二甲基甲酰胺中≤30mg/ml |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | 7.89±0.20(Predicted) |
| 颜色 | 白色至米白色 |
NI-57 用途与合成方法
IC50: 3.1 nM (BRPF1), 46 nM (BRPF2 (BRD1)), 140 nM (BRPF3)
NI-57 is an inhibitor of bromodomain and plant homeodomain finger-containing (BRPF), with IC 50 s of 3.1, 46 and 140 nM for BRPF1, BRPF2 (BRD1) and BRPF3, respectively. NI-57 binds the BRD of BRPF1 with a K d of 31 ± 2 nM, BRD1 with a K d of 110 ± 13 nM, and BRPF3 with a K d of 410 ± 47 nM, whereas binding to BRD9 is weaker (K d 1000 ± 130 nM) measured by isothermal titration calorimetry. NI-57 shows less active effect on BRD9 (IC 50 , 520 nM) and BRD4 (BD1) (IC 50 , 3700 nM), TRIM24 (IC 50 , 1600 nM). NI-57 also inhibits BRPF BRDs in the nucleus, but shows little effect on the proliferation of many cancer cell lines with GI 50 s of 10.4 μM (NCI-H1703 cells), 14.7 μM (DMS114), 15.6 μM (HRA-19), and 16.6 μM (RERF-LC-Sq1). Furthermore, Inhibition on BRPF1 of NI-57 (10 μM) reduces the gene expression of CCL-22 by 27.7 ± 9.4%.
NI-57 has favorable oral bioavailability in mice.
